MX2017016106A - Composiciones de combinacion para tratar trastornos que requieren de la remocion o destruccion de proliferaciones celulares no deseadas. - Google Patents

Composiciones de combinacion para tratar trastornos que requieren de la remocion o destruccion de proliferaciones celulares no deseadas.

Info

Publication number
MX2017016106A
MX2017016106A MX2017016106A MX2017016106A MX2017016106A MX 2017016106 A MX2017016106 A MX 2017016106A MX 2017016106 A MX2017016106 A MX 2017016106A MX 2017016106 A MX2017016106 A MX 2017016106A MX 2017016106 A MX2017016106 A MX 2017016106A
Authority
MX
Mexico
Prior art keywords
destruction
requiring removal
treating disorders
combination compositions
unwanted cellular
Prior art date
Application number
MX2017016106A
Other languages
English (en)
Inventor
Averback Paul
Original Assignee
Nymox Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nymox Corp filed Critical Nymox Corp
Publication of MX2017016106A publication Critical patent/MX2017016106A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Las modalidades incluyen métodos para tratar condiciones que requieren de la remoción o destrucción de elementos celulares, tales como tumores benignos o malignos utilizando compuestos basados en pequeños péptidos en combinación con agentes activos adicionales. El método incluye, pero no se limita a, administrar los compuestos de forma intramuscular, oral, intravenosa, intratecal, intraprostática, intratumoral, intranasal, tópica, transdérmica, etc., ya que solo o conjugados a un portador para un mamífero con la necesidad de los mismos.
MX2017016106A 2015-06-12 2016-06-13 Composiciones de combinacion para tratar trastornos que requieren de la remocion o destruccion de proliferaciones celulares no deseadas. MX2017016106A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14/738,551 US20160361380A1 (en) 2015-06-12 2015-06-12 Combination compositions for treating disorders requiring removal or destruction of unwanted cellular proliferations
PCT/IB2016/053483 WO2016199112A1 (en) 2015-06-12 2016-06-13 Combination compositions for treating disorders requiring removal or destruction of unwanted cellular proliferations

Publications (1)

Publication Number Publication Date
MX2017016106A true MX2017016106A (es) 2018-08-01

Family

ID=56137476

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017016106A MX2017016106A (es) 2015-06-12 2016-06-13 Composiciones de combinacion para tratar trastornos que requieren de la remocion o destruccion de proliferaciones celulares no deseadas.

Country Status (22)

Country Link
US (1) US20160361380A1 (es)
EP (1) EP3307299B1 (es)
JP (1) JP6941605B2 (es)
KR (1) KR20180035788A (es)
CN (1) CN108135974A (es)
AU (1) AU2016275368B2 (es)
CA (1) CA2992174A1 (es)
DK (1) DK3307299T3 (es)
EA (1) EA038314B1 (es)
ES (1) ES2876358T3 (es)
HK (1) HK1254080A1 (es)
HR (1) HRP20210462T1 (es)
HU (1) HUE053665T2 (es)
IL (1) IL256230B (es)
LT (1) LT3307299T (es)
MX (1) MX2017016106A (es)
PL (1) PL3307299T3 (es)
PT (1) PT3307299T (es)
RS (1) RS61685B1 (es)
SI (1) SI3307299T1 (es)
WO (1) WO2016199112A1 (es)
ZA (1) ZA201800083B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11628202B2 (en) 2015-07-24 2023-04-18 Nymox Corporation Methods of reducing the need for surgery in patients suffering from benign prostatic hyperplasia
US10172910B2 (en) 2016-07-28 2019-01-08 Nymox Corporation Method of preventing or reducing the incidence of acute urinary retention
US10532081B2 (en) * 2016-09-07 2020-01-14 Nymox Corporation Method of ameliorating or preventing the worsening or the progression of symptoms of BPH
US10335453B2 (en) 2017-03-01 2019-07-02 Nymox Corporation Compositions and methods for improving sexual function
WO2019055648A1 (en) * 2017-09-14 2019-03-21 Tufts Medical Center, Inc. METHOD OF TREATMENT AND DIAGNOSIS OF PROSTATE CANCER
US10835538B2 (en) 2018-03-28 2020-11-17 Nymox Corporation Method of treating benign prostatic hyperlasia with antibiotics
US20200061150A1 (en) 2018-08-23 2020-02-27 Nymox Corporation Method of inducing selective prostate glandular pharmaco-ablation with sparing of nerves and preservation of sexual function
US11278588B2 (en) 2019-05-13 2022-03-22 Nymox Corporation Method of treating lower urinary tract symptoms with fexapotide triflutate
US20200360466A1 (en) 2019-05-13 2020-11-19 Nymox Corporation Method of improving lower urinary tract symptoms
US11298400B2 (en) 2019-05-13 2022-04-12 Nymox Corporation Method of enhancing the therapeutic efficacy of fexapotide triflutate in treating LUTS
US11231421B2 (en) 2019-07-31 2022-01-25 Nymox Corporation Methods of treating multifocal cancer
US11331374B2 (en) 2019-07-31 2022-05-17 Nymox Corporation Focal treatment of prostate cancer

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3423507A (en) 1966-02-25 1969-01-21 Schering Corp Method of treating benign prostratic hypertrophy
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4329364A (en) 1974-09-11 1982-05-11 Schering Corporation Antiandrogenic agents and methods for the treatment of androgen dependent disease states
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
DE2817157A1 (de) 1978-04-17 1979-10-25 Schering Ag Verwendung von antioestrogenen und antigonadotrop wirkenden antiandrogenen zur prophylaxe und therapie der prostatahyperplasie
FR2465486A1 (fr) 1979-09-21 1981-03-27 Roussel Uclaf Nouvelle application utilisant la lh-rh ou des agonistes
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
DE3121153A1 (de) 1981-05-22 1982-12-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen "verwendung von aromatase-hemmern zur prophylaxe und therapie der prostatahyperplasie"
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
DE3474511D1 (en) 1983-11-01 1988-11-17 Terumo Corp Pharmaceutical composition containing urokinase
US4760053A (en) 1984-08-02 1988-07-26 Fernand Labrie Combination therapy for selected sex steroid dependent cancers
US4659695A (en) 1985-02-08 1987-04-21 Fernand Labrie Method of treatment of prostate cancer
US4775660A (en) 1984-08-02 1988-10-04 Fernand Labrie Treatment of breast cancer by combination therapy
FR2582513B1 (fr) 1985-05-28 1988-08-05 Synthelabo Compositions pharmaceutiques contenant de l'alfuzosine
US5158881A (en) 1987-11-17 1992-10-27 Brown University Research Foundation Method and system for encapsulating cells in a tubular extrudate in separate cell compartments
US5212176A (en) 1990-06-29 1993-05-18 Abbott Laboratories R(+)-terazosin
NZ241979A (en) 1991-03-20 1996-01-26 Merck & Co Inc Treatment of benign prostatic hyperplasia using 5alpha-reductase inhibitor and an alpha1-adrenergic recepter blocker
WO1994008040A1 (en) 1992-09-25 1994-04-14 Synaptic Pharmaceutical Corporation Dna encoding human alpha 1 adrenergic receptors and uses thereof
US5403847A (en) 1992-11-13 1995-04-04 Synaptic Pharmaceutical Corporation Use of α1C specific compounds to treat benign prostatic hyperlasia
EE9700209A (et) 1994-11-16 1998-04-15 Synaptic Pharmaceutical Corporation Dihüdropürimidiinid ja nende kasutamine
WO2000028004A1 (en) 1998-11-10 2000-05-18 The University Of North Carolina At Chapel Hill Virus vectors and methods of making and administering the same
BR0207638A (pt) 2001-03-08 2004-07-27 Nymox Pharmaceuticals Corp Métodos de uso de proteìna de filamento neural para tratar tumores e outras condições que requerem a remoção ou destruição de células
WO2002089841A2 (en) * 2001-05-04 2002-11-14 Nymox Corporation Method of preventing cell death using antibodies to neural thread proteins
BR0209630A (pt) * 2001-05-16 2004-03-30 Nymox Corp Método de impedir morte de célula usando segmentos de proteìnas em cadeia neurais
ATE350396T1 (de) 2001-05-25 2007-01-15 Nymox Corp Von neurofilamentproteinen abgeleitete peptide und deren medizinische verwendung
CN100432103C (zh) * 2001-07-19 2008-11-12 尼莫克斯股份有限公司 有效治疗肿瘤和其它需要除去或破坏细胞的疾病的肽
CN100475843C (zh) 2001-07-19 2009-04-08 尼莫克斯股份有限公司 有效治疗肿瘤和其它需要除去或破坏细胞的疾病的肽
US7317077B2 (en) 2001-11-16 2008-01-08 Nymox Pharmaceutical Corporation Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
EP1714979A3 (en) * 2001-11-16 2007-04-25 Nymox Corporation Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
EP2441454B1 (en) * 2005-11-15 2015-09-16 JC (Wuxi) COMPANY, Inc. The use of isothiocyanate compounds in treating prostatitis
ES2400920T3 (es) * 2006-02-28 2013-04-15 Nymox Corporation Péptidos eficaces en el tratamiento de tumores y otras afecciones que requieren la eliminación o la destrucción de células
JP2009529503A (ja) 2006-03-10 2009-08-20 ナイモックス コーポレーション 神経糸状タンパク質由来ペプチドを用いて癌を予防するまたはその危険度または発生率を減少させる方法
WO2012109387A1 (en) * 2011-02-08 2012-08-16 Halozyme, Inc. Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia
CA2905438A1 (en) * 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses

Also Published As

Publication number Publication date
KR20180035788A (ko) 2018-04-06
EP3307299A1 (en) 2018-04-18
US20160361380A1 (en) 2016-12-15
LT3307299T (lt) 2021-04-12
PL3307299T3 (pl) 2021-07-05
AU2016275368B2 (en) 2022-03-03
CN108135974A (zh) 2018-06-08
DK3307299T3 (da) 2021-03-22
SI3307299T1 (sl) 2021-04-30
ZA201800083B (en) 2019-07-31
HUE053665T2 (hu) 2021-07-28
AU2016275368A1 (en) 2018-02-01
WO2016199112A1 (en) 2016-12-15
IL256230A (en) 2018-02-28
PT3307299T (pt) 2021-03-26
CA2992174A1 (en) 2016-12-15
JP6941605B2 (ja) 2021-09-29
HK1254080A1 (zh) 2019-07-12
HRP20210462T1 (hr) 2021-05-14
JP2018517772A (ja) 2018-07-05
EA038314B1 (ru) 2021-08-09
EP3307299B1 (en) 2020-12-23
RS61685B1 (sr) 2021-05-31
IL256230B (en) 2021-04-29
ES2876358T3 (es) 2021-11-12
EA201890045A1 (ru) 2018-05-31

Similar Documents

Publication Publication Date Title
MX2017016106A (es) Composiciones de combinacion para tratar trastornos que requieren de la remocion o destruccion de proliferaciones celulares no deseadas.
CR20190478A (es) Inhibidores de pd-1/pd-l1
MX2018001052A (es) Metodos para reducir la necesidad de cirugia en pacientes que padecen hiperplasia prostatica benigna.
AU2018236800B2 (en) DNA-PK inhibitors
GB2550804A (en) Method of treating disorders requiring destruction or removal of cells using a neural thread protein derived peptide
PH12018501084A1 (en) Heterocyclic compounds as immunomodulators
MX2022000789A (es) Compuestos heterociclicos como inmunomoduladores.
PH12016500953A1 (en) Tricyclic compounds as anticancer agents
EA201792204A1 (ru) Ингибиторы ido
MX2018005829A (es) Composiciones para tratar el cabello.
EA201591823A1 (ru) Ингибиторы ido
MX2016002075A (es) Inhibidores de indolamina 2,3-dioxigenasa (ido).
WO2014113429A3 (en) Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
MX2015017486A (es) Inhibidores de indolamina 2,3-dioxigenasa (dio).
PH12016500651A1 (en) Composition for treating and preventing benign prostatic hyperplasia
PH12017500615A1 (en) Ophthalmic composition comprising cyclosporine and trehalose
MX2018013164A (es) Compuestos novedosos de imidazopiridina sustituida como inhibidores de indolamina-2,3-dioxigenasa y/o triptofano-2,3-dioxigenasa.
NZ744323A (en) Compositions comprising 15-hepe and methods of using the same
MX2019000428A (es) Agentes y metodos para la prevencion o el tratamiento de infecciones por h. pylori.
MX370586B (es) Imidazolil enonas triciclicas como moduladores de inflamacion antioxidantes.
MX2019002698A (es) Metodo para mitigar o prevenir el empeoramiento o la progresion sintomas de hpb.
MX2018001315A (es) Inhibidores de fucosidasa.
MX2019010394A (es) Composiciones y metodos para mejorar la funcion sexual.
MX2019009235A (es) Compuestos antifibroticos.
MX2015013151A (es) Métodos de tratamiento de disquinesia y trastornos relacionados.